Raising capital has never been easy for small companies, but in today’s market, it’s particularly tough. Dilution-sensitive investors, sluggish risk appetite, and volatile valuations have made traditional equity financings costly and sometimes counterproductive. As a result, many issuers are leaning on secondary offerings and convertible notes. Traditionally, these non-dilutive, hybrid structures can help fund growth without eroding shareholder value.
This trend might only be theoretical, but it appears to be gaining momentum in term sheets and boardroom conversations, especially among companies demonstrating asset coverage, recurring revenue, or near-term catalysts. If so, businesses opt for solutions like revenue-based financing, royalty agreements (cue, Mr. Wonderful), and structured credit facilities that mirror private market playbooks. The goal is straightforward: raise capital without permanently expanding the share count.
Revenue-based financing: investors receive a fixed percentage of top-line revenue until a set return is met. This style of financing is gaining renewed traction among public companies with predictable cash flows. Royalty financing, commonly used by our biotech and mining clients, is being adapted for firms with monetizable intellectual property or contractual revenue streams. Structured debt instruments, often including warrant coverage, can also bridge capital needs while preserving the upside. Companies can also layer these structures to build flexible, multi-tiered capital stacks that limit dilution and minimize balance sheet risk.
What’s driving this shift? Part of it is simple math. With valuations depressed, issuing equity today can mean locking in dilution at unattractive levels. Boards and insiders, many of whom are major shareholders, are reluctant to accept that tradeoff. In parallel, non-bank lenders, flush with capital and seeking yield, are underwriting deals that resemble venture debt or middle-market loans but are tailored to the needs of smaller companies. Simultaneously, institutional investors are becoming more vocal about the long-term costs of serial equity issuance, pushing management teams to explore alternatives that better align with shareholder interests.
Medexus Pharma, a Toronto-based small-cap pharmaceutical firm, secured royalty-based financing tied to U.S. product sales, avoiding dilution while funding growth. NextPlay Technologies entered a $15 million revenue-share agreement, giving it access to non-dilutive capital when its stock price offered little strategic leverage. Kaleyra, Inc., a cloud communications company, used structured debt with warrant coverage to support expansion and ultimately set it up for acquisition. These are not one-off cases. They are part of a shift toward creative capital formation in public markets.
To be transparent, these structures come with tradeoffs. Non-dilutive financing is rarely cheap. Revenue-based repayment can strain cash flow. Royalty deals have the potential to cap long-term upside. Structured credit often includes onerous covenants, board-level oversight, or restrictions on future borrowing. But in many situations, these constraints are acceptable, or even welcome, if they reduce the reliance on dilution and signal fiscal discipline to the market.
Investors, too, are adapting. Many view non-dilutive financing as a way to gain yield and potential upside without assuming the same equity risk. For companies, the challenge is to structure these deals in ways that fit operational realities without overpromising—never easy.
This financing evolution reflects our current lending atmosphere, with traditional equity still being the most straightforward and efficient option in a more business-friendly environment. However, given today’s environment, companies that approach capital formation with creativity, discipline, and an eye toward long-term value will be rewarded.
In summary, the rise of non-dilutive capital is less about financial engineering and more about signaling. It’s a way for companies to say: We understand the cost of capital. We value shareholder equity. We’re willing to explore structures that match our business realities while preserving strategic flexibility, and the message resonates with boards, shareholders, and capital markets.
